The epirubicin/docetaxel combination is one of the most active and best tolerated taxane/anthracycline combinations. In this phase II trial, we will further evaluate the feasibility, safety and effectiveness of the docetaxel/epirubicin combination, when administered as first-line treatment for metastatic breast cancer.
Upon determination of eligibility, all patients will receive: Docetaxel + Epirubicin Both drugs will be repeated at 21-day intervals
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
90
Clinical response rate of the docetaxel/epirubicin combination in the first-line treatment of patients with metastatic breast cancer
Safety of the docetaxel/epirubicin combination in the first-line treatment of patients with metastatic breast cancer
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.